Adaptilens Announces $17.5M in Series A Financing​
We are thrilled to announce that Adaptilens has secured $17.5 million in Series A financing, led by Xontogeny and Perceptive Xontogeny Venture Fund, with participation from Pillar VC and Accanto Partners. This significant investment will accelerate the development of our innovative accommodating intraocular lenses, bringing us closer to restoring natural focusing ability for patients worldwide.
